Equities

Carmell Corp

CTCX:NAQ

Carmell Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.4114
  • Today's Change0.021 / 5.49%
  • Shares traded87.38k
  • 1 Year change-91.11%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Carmell Corporation (Carmell) is a bio-aesthetics company focused on skin and hair health. The Company utilizes the Carmell Secretome to support skin and hair health. The Carmell Secretome consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from United States Food and Drug Administration-approved tissue banks. The Company has developed a novel micellar nanoparticle formulation that enables delivery of lipophilic and hydrophilic ingredients without relying on the harmful excipients that are used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Additionally, Carmell’s micellar formulations do not utilize mineral or vegetable oils across their entire product line and are designed to be non-comedogenic. The Company is also developing a line of men’s products and a line of topical haircare products.

  • Revenue in USD (TTM)12.32k
  • Net income in USD-15.97m
  • Incorporated2021
  • Employees9.00
  • Location
    Carmell Corp2403 Sidney Street, Suite 300PITTSBURGH 15203United StatesUSA
  • Phone+1 (412) 894-8248
  • Fax+1 (302) 636-5454
  • Websitehttps://www.carmellrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
TFF Pharmaceuticals Inc1.20m-19.39m8.01m19.00--1.28--6.66-7.95-7.950.46591.810.1043--3.5163,293.68-168.10-79.57-212.66-83.41-----1,612.04-8,687.66----0.00--48.01--33.13------
Correlate Energy Corp5.65m-34.51m8.02m19.00------1.42-0.8359-0.83590.1457-0.04611.50--11.12297,377.40-915.61-315.47-----6.4515.42-610.79-201.03---1.07----122.2046.12-78.54------
Cell MedX Corp0.00-142.49k8.03m0.00---------0.0021-0.00210.00-0.00280.00-------190.76-703.78------84.03---2,996.54---4.35-----100.00--71.22------
Vitro Biopharma Inc2.11m-10.44m8.05m10.00------3.82-2.35-2.350.4745-1.690.27651.7120.61210,873.00-136.91---1,046.98--83.48---495.08--0.1865-4.19-----46.45--31.01------
Nascent Biotech Inc0.00-1.92m8.08m-----------0.012-0.0120.00-0.0030.00-------1,256.81-708.50-----------589.83------------25.47------
Mustang Bio Inc0.00-32.06m8.27m80.00---------2.91-2.910.00-0.23840.00----0.00-170.53-70.02-727.24-79.98--------------------33.44---60.75--
Silexion Therapeutics Corp0.00-523.87k8.50m0.00--1.33-----0.1403-0.14030.000.65590.00-------3.13---3.77--------------0.00-------54.96------
Carmell Corp12.32k-15.97m8.60m9.00------698.09-1.53-1.440.0006-0.0656------1,368.89--------58.73---129,263.60--0.6901-----------75.70------
ABVC Biopharma Inc136.40k-11.37m8.64m16.00--1.01--63.36-1.78-1.780.01720.68820.0114--0.42138,525.00-99.79-103.38-197.79-231.54-24.1176.25-8,762.13-2,019.89---2.500.1873---84.2885.3935.97------
Soligenix Inc494.62k-7.04m8.71m13.00--1.70--17.61-9.58-9.580.61522.250.0418--8.7038,047.69-59.45-75.40-121.64-154.328.7522.83-1,423.81-620.02----0.4421---11.54-30.6755.50------
Calidi Biotherapeutics Inc0.00-24.92m8.81m41.00---------5.41-5.410.00-1.820.00----0.00-279.89-----------------27.58-----100.00---14.90------
Viracta Therapeutics Inc0.00-45.34m8.82m40.00---------1.16-1.160.000.06780.00----0.00-83.82-86.35-140.98-106.38-------11,853.94---59.780.8753-------3.78------
Molecular Templates Inc25.47m-15.63m8.89m62.00--1.25--0.349-2.70-2.704.241.080.8189--47.65410,806.40-50.24-51.78-113.26-73.14-----61.35-228.33----0.00--190.1033.9691.24---48.87--
BioCardia Inc428.00k-8.56m8.89m16.00------20.78-5.40-5.400.2636-0.92330.0923--6.8526,750.00-184.48-107.34-1,075.25-154.17-----1,999.77-1,779.24---------64.72-5.262.82---28.89--
Inhibikase Therapeutics Inc79.57k-18.38m8.96m8.00--1.70--112.57-2.93-2.930.01260.70630.0051----9,946.25-117.93-66.49-148.63-85.55-----23,102.16-1,139.14----0.00--111.03-42.21-5.40------
Portage Biotech Inc0.00-71.08m9.15m7.00--3.64-----68.81-68.810.002.390.00----0.00-137.29-30.53-143.21-40.02------------0.02------27.98------
Data as of Sep 20 2024. Currency figures normalised to Carmell Corp's reporting currency: US Dollar USD

Institutional shareholders

15.94%Per cent of shares held by top holders
HolderShares% Held
Meteora Capital LLCas of 30 Jun 20241.74m8.32%
Sandstone Asset Management, Inc.as of 04 Apr 20241.02m4.87%
The Vanguard Group, Inc.as of 30 Jun 2024179.59k0.86%
Carnegie Mellon University (Investment Management)as of 30 Jun 2024103.06k0.49%
Geode Capital Management LLCas of 30 Jun 202483.14k0.40%
Linden Advisors LPas of 30 Jun 202475.00k0.36%
Warberg Asset Management LLCas of 30 Jun 202445.00k0.22%
Northern Trust Investments, Inc.(Investment Management)as of 30 Jun 202439.69k0.19%
BlackRock Fund Advisorsas of 30 Jun 202435.42k0.17%
Northern Trust Global Investments Ltd.as of 30 Jun 202413.17k0.06%
More ▼
Data from 04 Apr 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.